Preferences for tapering biologic disease-modifying antirheumatic drugs among people with rheumatoid arthritis - a discrete choice experiment.

For individuals with RA, making decisions about tapering bDMARDs involves considering several factors, with the most important determinants identified as dosing frequency and the risk of disease flare. Understanding patient perspectives of bDMARD tapering may enable physicians to make patient-focused shared healthcare decisions.